Telehealth in Gynecologic Oncology Clinical Trials
Despite notable limitations, patients, research staff, and clinicians recommended continued utilization of telehealth and remote clinical trial operations in clinical trials. Future clinical trial designs should consider telehealth inclusion.
Authors
- Anna Jo Bodurtha Smith (ORCID: https://orcid.org/0000-0002-7692-773X)
- Nathanael Koelper (ORCID: https://orcid.org/0000-0002-3977-6856)
- Katharine A. Rendle (ORCID: https://orcid.org/0000-0002-7761-8728)
- Fiona Simpkins (ORCID: https://orcid.org/0000-0002-0840-2368)
- Emily Gleason (ORCID: https://orcid.org/0000-0003-4789-995X)
- Leslie Andriani (ORCID: https://orcid.org/0000-0002-1435-9722)
- Andrea Bilger (ORCID: https://orcid.org/0000-0002-4838-4731)
- Megan Grabill (ORCID: https://orcid.org/0000-0002-6699-2992)
- Emily Ko (ORCID: https://orcid.org/0000-0002-9438-1566)
- Eion Plenn
- Linda M. Saikali
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- O&G Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1097/og9.0000000000000051
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Pfizer
- AstraZeneca
- University of Pennsylvania
- Division of Cancer Prevention, National Cancer Institute
- Johns Hopkins University
- Ovarian Cancer Research Alliance
- Eisai
- Sierra Oncology
- National Institutes of Health
- National Cancer Institute